Disc Medicine, Inc. is facing a class action lawsuit after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This announcement caused the company's stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securities claims and preparing a class action to help investors recover losses without upfront fees. Investors who purchased Disc Medicine securities may be eligible to join the lawsuit for compensation.
Shares of American Bitcoin Corp, co-launched by Eric Trump, have fallen over 95% from their peak, erasing more than $600 million from Eric Trump's 6% ownership. The company shifted from an AI infrastructure focus to Bitcoin mining, a move that has un...
Tom Lee reaffirms that Ethereum will be central as traditional finance and cryptocurrency markets merge. Bitmine's Ethereum treasury has grown to over 5.74 million ETH, about 4.8% of total supply, highlighting strong corporate confidence. Lee links E...
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
A cryptocurrency expert recommends allocating $1,000 across five digital assets and a stablecoin buffer to balance security and growth potential. The portfolio assigns 40% to Bitcoin and 25% to Ethereum, reflecting their market dominance and institut...
After eight consecutive weeks of outflows totaling over $8 billion, Bitcoin ETFs recorded nearly $200 million in net inflows last week, marking a positive shift for the first time in two months. Ethereum ETFs also saw their best week since April with...
